JPRN-jRCT2080221761未知2 期
Phase 2b, Double-Blind, Parallel-group Study of S-2367 in Obese Patients
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Main inclusion criteria
- •1. With BMI >=25.0
- •2. With visceral fat area >=100 cm2 as determined with abdominal CT
- •3. Previously diagnosed with glucose intolerance or type 2 diabetes,
- •and HbA1c (NGSP) >=6.5% to <9.4%
- •4. Previously diagnosed as dyslipidemia with fasting serum triglycerides >=150 mg/dL
- •and/or fasting serum HDL-cholesterol <40 mg/d
排除标准
- 未提供
研究者
相似试验
未知
2 期
Phase 2, Double-Blind, Parallel-group Study of S-2367 in Obese Patients with Hypertension and DyslipidemiaJPRN-jRCT2080221085SHIONOGI & CO., LTD.120
未知
2 期
Phase 2, Double-Blind, Parallel-group Study of S-2367 in Obese PatientsObesity (BMI:>=25.0) with glucose intolerance or type 2 diabetes and dyslipidemiaJPRN-jRCT2080221077SHIONOGI & CO., LTD.280
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-DEKeyNeurotek Pharmaceuticals AG108
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-CZKeyNeurotek Pharmaceuticals AG108
进行中（未招募）
不适用
A double-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-BEKeyNeurotek Pharmaceuticals AG108